4CPS-111 Clinical and economic impact of infliximab biosimilar Inflectra in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis naïve and switched patients: 5 years of follow-up

Background and importanceRheumatoid arthritis (RA), psoriatic arthritis (AP) and ankylosing spondylitis (AS) have a considerable impact on healthcare budgets.Aim and objectivesThe aim of this study was to determine the persistence, clinical and economic impact of the use of Inflectra in RA, AP and A...

Full description

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2020-03, Vol.27 (Suppl 1), p.A99-A99
Main Authors: Borras, J, Gracia-Pérez, A, Valcuende Rosique, A, Castera, MDe, Rosique, JD, Abad, FJ
Format: Article
Language:English
Subjects:
Cost control
Economic impact
Immunotherapy
Monoclonal antibodies
Rheumatoid arthritis
TNF inhibitors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page A99
container_issue Suppl 1
container_start_page A99
container_title European journal of hospital pharmacy. Science and practice
container_volume 27
creator Borras, J
Gracia-Pérez, A
Valcuende Rosique, A
Castera, MDe
Rosique, JD
Abad, FJ
description Background and importanceRheumatoid arthritis (RA), psoriatic arthritis (AP) and ankylosing spondylitis (AS) have a considerable impact on healthcare budgets.Aim and objectivesThe aim of this study was to determine the persistence, clinical and economic impact of the use of Inflectra in RA, AP and AS naïve and Remicade switched patients.Material and methodsThis was an observational, retrospective cohort study of patients treated with Inflectra for more than 6 months, between June 2015 and September 2019. We collected age, sex, indication and persistence of Inflectra naïve and switched patients. Safety was also assessed. We determined the real cost of Inflectra treatment for each patient from individualised intravenous administration, and correlated dates during the study period were collected from DISPENSA (Oncopharm). We simulated the real cost for these patients if they received Remicade. Cost savings were calculated using official Spanish prices for Inflectra and Remicade.ResultsFrom June 2015 to September 2019, 62 patients (38 women; aged 52±20 years; weight 75±27 kg), 31 with AS, 18 with RA and 13 with AP were treated; 33 (53%) were naïve patients (15 AS, 13 RA, 5 AP) and 29 (47%) were Remicade pretreated patients (16 AS, 5 RA, 8 AP). By September 2019, 33 (54%) patients continued on Inflectra treatment (11 naïve patients and 22 Remicade pretreated patients) in clinical remission (DAS 28
doi_str_mv 10.1136/ejhpharm-2020-eahpconf.212
format article
fullrecord <record><control><sourceid>proquest_bmj_p</sourceid><recordid>TN_cdi_proquest_journals_2382406546</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2382406546</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1262-338243796dc1fa064b0b9954a4472193ed7c41529dba7189db2cb79dc93109bd3</originalsourceid><addsrcrecordid>eNo9kctu1TAQhiMEElXpO1iwJa1vSWp26IhLpUogAWtrfAnxIbGN7UPJjk2fh4dgwXvwJDinlNWMxv_845mvaZ4SfE4I6y_sfooTpKWlmOLWwhR18OM5JfRBc0IxH1ohev7wf971j5uznJ3CHWOXgjNx0vzmu_cfWkLInx-3u9l5p2FG4A2y1SssTiO3RNAFhRE5P87uu1tAIeVCdoubIaGrWrW6JKjvKE32sEAJziBIZUquuPwcxRySg1LNjsUQoUzrcQr4L-tcrfxnlGPwZp23DuTh189v9qjIN67oyRpUm5z1Jb9AHVotpLx9aQzzHG7aQ3zSPBphzvbsXzxtPr1-9XH3tr1-9-Zq9_K6VYT2tK17U84G0RtNRsA9V1jVw3DgfKBEMGsGzUlHhVEwkMsaqFaDMFowgoUy7LR5ducbU_h6sLnIfTgkX0dKunnjvuN9VXV3KrXsZUz1ZGmVBMsNm7zHJjds8h6brNjYX4zglj4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2382406546</pqid></control><display><type>article</type><title>4CPS-111 Clinical and economic impact of infliximab biosimilar Inflectra in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis naïve and switched patients: 5 years of follow-up</title><source>NCBI_PubMed Central（免费）</source><creator>Borras, J ; Gracia-Pérez, A ; Valcuende Rosique, A ; Castera, MDe ; Rosique, JD ; Abad, FJ</creator><creatorcontrib>Borras, J ; Gracia-Pérez, A ; Valcuende Rosique, A ; Castera, MDe ; Rosique, JD ; Abad, FJ</creatorcontrib><description>Background and importanceRheumatoid arthritis (RA), psoriatic arthritis (AP) and ankylosing spondylitis (AS) have a considerable impact on healthcare budgets.Aim and objectivesThe aim of this study was to determine the persistence, clinical and economic impact of the use of Inflectra in RA, AP and AS naïve and Remicade switched patients.Material and methodsThis was an observational, retrospective cohort study of patients treated with Inflectra for more than 6 months, between June 2015 and September 2019. We collected age, sex, indication and persistence of Inflectra naïve and switched patients. Safety was also assessed. We determined the real cost of Inflectra treatment for each patient from individualised intravenous administration, and correlated dates during the study period were collected from DISPENSA (Oncopharm). We simulated the real cost for these patients if they received Remicade. Cost savings were calculated using official Spanish prices for Inflectra and Remicade.ResultsFrom June 2015 to September 2019, 62 patients (38 women; aged 52±20 years; weight 75±27 kg), 31 with AS, 18 with RA and 13 with AP were treated; 33 (53%) were naïve patients (15 AS, 13 RA, 5 AP) and 29 (47%) were Remicade pretreated patients (16 AS, 5 RA, 8 AP). By September 2019, 33 (54%) patients continued on Inflectra treatment (11 naïve patients and 22 Remicade pretreated patients) in clinical remission (DAS 28 &lt;2.6 or BASDAI &lt;2). Twenty-nine patients discontinued therapy: 24 due to relapse of their rheumatology condition and 5 patients due to adverse reactions. All patients receiving Inflectra presented persistence at 24.4±7.4 months (AS 22.7±3.7, RA 19.2±5.4, AP 31.7±6.7). Persistence in naïve patients was 19.1±4.4 months (AS 19.1±4.7, RA 13.8±3.2, AP 24.5±10.4) and in Remicade pretreated patients 29.7±5.8 months (AS 26.5±6.5, RA 24.6±7.2, AP 37.9±8.1). Total associated costs of Inflectra treatment during the observation period were 901 840€. If these patients had been treated with Remicade, the total cost of therapy would have been 1 099 803€. Implementation of this procedure saved 197 964€ over 5 years.Conclusion and relevanceInflectra produced cost savings when used in anti-TNFα drug naïve and anti-TNFα pretreated patients. At a time when therapy cost is an unavoidable component of healthcare treatment decisions, Inflectra could be a cost effective option for patients with RA, AP and AS.References and/or acknowledgementsNo conflict of interest.</description><identifier>ISSN: 2047-9956</identifier><identifier>EISSN: 2047-9964</identifier><identifier>DOI: 10.1136/ejhpharm-2020-eahpconf.212</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Cost control ; Economic impact ; Immunotherapy ; Monoclonal antibodies ; Rheumatoid arthritis ; TNF inhibitors</subject><ispartof>European journal of hospital pharmacy. Science and practice, 2020-03, Vol.27 (Suppl 1), p.A99-A99</ispartof><rights>Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2020 Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Borras, J</creatorcontrib><creatorcontrib>Gracia-Pérez, A</creatorcontrib><creatorcontrib>Valcuende Rosique, A</creatorcontrib><creatorcontrib>Castera, MDe</creatorcontrib><creatorcontrib>Rosique, JD</creatorcontrib><creatorcontrib>Abad, FJ</creatorcontrib><title>4CPS-111 Clinical and economic impact of infliximab biosimilar Inflectra in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis naïve and switched patients: 5 years of follow-up</title><title>European journal of hospital pharmacy. Science and practice</title><description>Background and importanceRheumatoid arthritis (RA), psoriatic arthritis (AP) and ankylosing spondylitis (AS) have a considerable impact on healthcare budgets.Aim and objectivesThe aim of this study was to determine the persistence, clinical and economic impact of the use of Inflectra in RA, AP and AS naïve and Remicade switched patients.Material and methodsThis was an observational, retrospective cohort study of patients treated with Inflectra for more than 6 months, between June 2015 and September 2019. We collected age, sex, indication and persistence of Inflectra naïve and switched patients. Safety was also assessed. We determined the real cost of Inflectra treatment for each patient from individualised intravenous administration, and correlated dates during the study period were collected from DISPENSA (Oncopharm). We simulated the real cost for these patients if they received Remicade. Cost savings were calculated using official Spanish prices for Inflectra and Remicade.ResultsFrom June 2015 to September 2019, 62 patients (38 women; aged 52±20 years; weight 75±27 kg), 31 with AS, 18 with RA and 13 with AP were treated; 33 (53%) were naïve patients (15 AS, 13 RA, 5 AP) and 29 (47%) were Remicade pretreated patients (16 AS, 5 RA, 8 AP). By September 2019, 33 (54%) patients continued on Inflectra treatment (11 naïve patients and 22 Remicade pretreated patients) in clinical remission (DAS 28 &lt;2.6 or BASDAI &lt;2). Twenty-nine patients discontinued therapy: 24 due to relapse of their rheumatology condition and 5 patients due to adverse reactions. All patients receiving Inflectra presented persistence at 24.4±7.4 months (AS 22.7±3.7, RA 19.2±5.4, AP 31.7±6.7). Persistence in naïve patients was 19.1±4.4 months (AS 19.1±4.7, RA 13.8±3.2, AP 24.5±10.4) and in Remicade pretreated patients 29.7±5.8 months (AS 26.5±6.5, RA 24.6±7.2, AP 37.9±8.1). Total associated costs of Inflectra treatment during the observation period were 901 840€. If these patients had been treated with Remicade, the total cost of therapy would have been 1 099 803€. Implementation of this procedure saved 197 964€ over 5 years.Conclusion and relevanceInflectra produced cost savings when used in anti-TNFα drug naïve and anti-TNFα pretreated patients. At a time when therapy cost is an unavoidable component of healthcare treatment decisions, Inflectra could be a cost effective option for patients with RA, AP and AS.References and/or acknowledgementsNo conflict of interest.</description><subject>Cost control</subject><subject>Economic impact</subject><subject>Immunotherapy</subject><subject>Monoclonal antibodies</subject><subject>Rheumatoid arthritis</subject><subject>TNF inhibitors</subject><issn>2047-9956</issn><issn>2047-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNo9kctu1TAQhiMEElXpO1iwJa1vSWp26IhLpUogAWtrfAnxIbGN7UPJjk2fh4dgwXvwJDinlNWMxv_845mvaZ4SfE4I6y_sfooTpKWlmOLWwhR18OM5JfRBc0IxH1ohev7wf971j5uznJ3CHWOXgjNx0vzmu_cfWkLInx-3u9l5p2FG4A2y1SssTiO3RNAFhRE5P87uu1tAIeVCdoubIaGrWrW6JKjvKE32sEAJziBIZUquuPwcxRySg1LNjsUQoUzrcQr4L-tcrfxnlGPwZp23DuTh189v9qjIN67oyRpUm5z1Jb9AHVotpLx9aQzzHG7aQ3zSPBphzvbsXzxtPr1-9XH3tr1-9-Zq9_K6VYT2tK17U84G0RtNRsA9V1jVw3DgfKBEMGsGzUlHhVEwkMsaqFaDMFowgoUy7LR5ducbU_h6sLnIfTgkX0dKunnjvuN9VXV3KrXsZUz1ZGmVBMsNm7zHJjds8h6brNjYX4zglj4</recordid><startdate>202003</startdate><enddate>202003</enddate><creator>Borras, J</creator><creator>Gracia-Pérez, A</creator><creator>Valcuende Rosique, A</creator><creator>Castera, MDe</creator><creator>Rosique, JD</creator><creator>Abad, FJ</creator><general>BMJ Publishing Group LTD</general><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>202003</creationdate><title>4CPS-111 Clinical and economic impact of infliximab biosimilar Inflectra in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis naïve and switched patients: 5 years of follow-up</title><author>Borras, J ; Gracia-Pérez, A ; Valcuende Rosique, A ; Castera, MDe ; Rosique, JD ; Abad, FJ</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1262-338243796dc1fa064b0b9954a4472193ed7c41529dba7189db2cb79dc93109bd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Cost control</topic><topic>Economic impact</topic><topic>Immunotherapy</topic><topic>Monoclonal antibodies</topic><topic>Rheumatoid arthritis</topic><topic>TNF inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Borras, J</creatorcontrib><creatorcontrib>Gracia-Pérez, A</creatorcontrib><creatorcontrib>Valcuende Rosique, A</creatorcontrib><creatorcontrib>Castera, MDe</creatorcontrib><creatorcontrib>Rosique, JD</creatorcontrib><creatorcontrib>Abad, FJ</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>European journal of hospital pharmacy. Science and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Borras, J</au><au>Gracia-Pérez, A</au><au>Valcuende Rosique, A</au><au>Castera, MDe</au><au>Rosique, JD</au><au>Abad, FJ</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>4CPS-111 Clinical and economic impact of infliximab biosimilar Inflectra in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis naïve and switched patients: 5 years of follow-up</atitle><jtitle>European journal of hospital pharmacy. Science and practice</jtitle><date>2020-03</date><risdate>2020</risdate><volume>27</volume><issue>Suppl 1</issue><spage>A99</spage><epage>A99</epage><pages>A99-A99</pages><issn>2047-9956</issn><eissn>2047-9964</eissn><abstract>Background and importanceRheumatoid arthritis (RA), psoriatic arthritis (AP) and ankylosing spondylitis (AS) have a considerable impact on healthcare budgets.Aim and objectivesThe aim of this study was to determine the persistence, clinical and economic impact of the use of Inflectra in RA, AP and AS naïve and Remicade switched patients.Material and methodsThis was an observational, retrospective cohort study of patients treated with Inflectra for more than 6 months, between June 2015 and September 2019. We collected age, sex, indication and persistence of Inflectra naïve and switched patients. Safety was also assessed. We determined the real cost of Inflectra treatment for each patient from individualised intravenous administration, and correlated dates during the study period were collected from DISPENSA (Oncopharm). We simulated the real cost for these patients if they received Remicade. Cost savings were calculated using official Spanish prices for Inflectra and Remicade.ResultsFrom June 2015 to September 2019, 62 patients (38 women; aged 52±20 years; weight 75±27 kg), 31 with AS, 18 with RA and 13 with AP were treated; 33 (53%) were naïve patients (15 AS, 13 RA, 5 AP) and 29 (47%) were Remicade pretreated patients (16 AS, 5 RA, 8 AP). By September 2019, 33 (54%) patients continued on Inflectra treatment (11 naïve patients and 22 Remicade pretreated patients) in clinical remission (DAS 28 &lt;2.6 or BASDAI &lt;2). Twenty-nine patients discontinued therapy: 24 due to relapse of their rheumatology condition and 5 patients due to adverse reactions. All patients receiving Inflectra presented persistence at 24.4±7.4 months (AS 22.7±3.7, RA 19.2±5.4, AP 31.7±6.7). Persistence in naïve patients was 19.1±4.4 months (AS 19.1±4.7, RA 13.8±3.2, AP 24.5±10.4) and in Remicade pretreated patients 29.7±5.8 months (AS 26.5±6.5, RA 24.6±7.2, AP 37.9±8.1). Total associated costs of Inflectra treatment during the observation period were 901 840€. If these patients had been treated with Remicade, the total cost of therapy would have been 1 099 803€. Implementation of this procedure saved 197 964€ over 5 years.Conclusion and relevanceInflectra produced cost savings when used in anti-TNFα drug naïve and anti-TNFα pretreated patients. At a time when therapy cost is an unavoidable component of healthcare treatment decisions, Inflectra could be a cost effective option for patients with RA, AP and AS.References and/or acknowledgementsNo conflict of interest.</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><doi>10.1136/ejhpharm-2020-eahpconf.212</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2047-9956
ispartof European journal of hospital pharmacy. Science and practice, 2020-03, Vol.27 (Suppl 1), p.A99-A99
issn 2047-9956
2047-9964
language eng
recordid cdi_proquest_journals_2382406546
source NCBI_PubMed Central（免费）
subjects Cost control
Economic impact
Immunotherapy
Monoclonal antibodies
Rheumatoid arthritis
TNF inhibitors
title 4CPS-111 Clinical and economic impact of infliximab biosimilar Inflectra in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis naïve and switched patients: 5 years of follow-up
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T06%3A15%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=4CPS-111%E2%80%85Clinical%20and%20economic%20impact%20of%20infliximab%20biosimilar%20Inflectra%20in%20rheumatoid%20arthritis,%20psoriatic%20arthropathy%20and%20ankylosing%20spondylitis%20na%C3%AFve%20and%20switched%20patients:%205%20years%20of%20follow-up&rft.jtitle=European%20journal%20of%20hospital%20pharmacy.%20Science%20and%20practice&rft.au=Borras,%20J&rft.date=2020-03&rft.volume=27&rft.issue=Suppl%201&rft.spage=A99&rft.epage=A99&rft.pages=A99-A99&rft.issn=2047-9956&rft.eissn=2047-9964&rft_id=info:doi/10.1136/ejhpharm-2020-eahpconf.212&rft_dat=%3Cproquest_bmj_p%3E2382406546%3C/proquest_bmj_p%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b1262-338243796dc1fa064b0b9954a4472193ed7c41529dba7189db2cb79dc93109bd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2382406546&rft_id=info:pmid/&rfr_iscdi=true